TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06351007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional education and psychological intervention
Description: In the two intervention groups, after the delivery of the meal plan, the educational and psychological intervention will begin, with a duration of 5 months. The main objective of the educational program in pre-dialysis patients is to delay the progression of renal damage and in dialysis patients is control of complications. The content of monthly educational sessions will be:~Month 1: proteins (predialysis group), potassium (dialysis group) Month 2: Sodium and fluids (predialysis group), phosphorus (dialysis group) Month 3: Phosphorus (predialysis group), sodium and fluids (dialysis group) Month 4: Potassium (predialysis group), proteins (dialysis group) Month 5: Myths and facts about food (both groups) Simultaneously, group psychological sessions will be carried out, aimed at modifying patient behaviors to increase adherence to diet plan through understanding the patient´s situation, promoting the development of healthy behaviors, barrier identification and goal setting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional education and psychological intervention
Description: In the two intervention groups, after the delivery of the meal plan, the educational and psychological intervention will begin, with a duration of 5 months. The main objective of the educational program in pre-dialysis patients is to delay the progression of renal damage and in dialysis patients is control of complications. The content of monthly educational sessions will be:~Month 1: proteins (predialysis group), potassium (dialysis group) Month 2: Sodium and fluids (predialysis group), phosphorus (dialysis group) Month 3: Phosphorus (predialysis group), sodium and fluids (dialysis group) Month 4: Potassium (predialysis group), proteins (dialysis group) Month 5: Myths and facts about food (both groups) Simultaneously, group psychological sessions will be carried out, aimed at modifying patient behaviors to increase adherence to diet plan through understanding the patient´s situation, promoting the development of healthy behaviors, barrier identification and goal setting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The control group (predialysis and dialysis patients) will receive standard nutritional care consisting of dietary prescription with follow-up for questions and adjustment of the meal plan every 2 months.~Based on the nutritional status, biochemical parameters and stage of renal disease, the meal plan will be calculated.~The characteristics of the diet will be as follows:~Calories - 30 kcal/Kg ideal body weight/day Protein - 0.8 g/kg ideal body weight/day (predialysis group) 1.2 kg ideal body weight/day (dialysis group) Carbohydrates - 50-60% of total calorie content Lipids - 30% of total calorie content Sodium \&lt; 2300 mg/day Potassium \&lt; 2000 mg/day Phosphorus \&lt; 1000 mg/day Fluids - Urine output + 500 ml
Study: NCT06001996

Intervention type: PROCEDURE
Intervention: Pericapsular nerve group (PENG) block
Description: Pericapsular nerve group (PENG) block: Using an in-plane approach with ultrasonographic imaging, the block needle reaches the fascial plane between the psoas muscle and the superior pubic ramus and local anaesthetic solution is injected.

Intervention type: PROCEDURE
Intervention: Suprainguinal fascia iliaca plane block
Description: Suprainguinal fascia iliaca plane block: The needle entering in plane from the caudal end of the ultrasound probe passes through the m. sartorius and into the musculus iliacus and fascia iliaca reaches. The fascia iliaca is passed with the needle and local anaesthetic solution is injected immediately under the fascia.
Study: NCT05948007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Description: 12 training sessions within 6 weeks will be provided. In each training session, participants will have neurofeedback training for five 3-minute training periods.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-neurofeedback training
Description: The Sham group has the same training dosage as the neurofeedback group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain management protocol
Description: The treatment components include sleep psychoeducation, sleep hygiene education, exercise consultation, and cognitive-behavioral pain management, i.e., practice in changing dysfunctional thoughts, setting and working toward behavioral goals, relaxation skills
Study: NCT06383156

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double lumen endotracheal tube
Description: correct position of LDLT during single lung ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double lumen endotracheal tube
Description: correct position of LDLT during single lung ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double lumen endotracheal tube
Description: correct position of LDLT during single lung ventilation
Study: NCT05989698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-mo System
Description: Patients will use C-mo System for a period of 24h, to assess cough characteristics.
Study: NCT04841980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Administration route: PO Rifaximin 400mg TDS for 2 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low FODMAP diet
Description: Low FODMAP diet under dietitian guidance for 4 weeks
Study: NCT04490395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engage PA
Description: Engage PA will consist of a 2-session intervention delivered to participants at the medical center or virtual visit by their study therapist, and includes a wearable personal fitness monitor for tracking their daily activity levels throughout.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual plus (TAU+)
Description: The comparison condition will receive treatment as usual throughout the study, and are given a wearable personal fitness monitor for tracking their daily activity levels throughout the study.
Study: NCT05341648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Warm-up: 5 minutes Aerobic Training Treadmill/cycle ergometer Frequency:3 days a week Intensity:40-70% of HR max(Start from 40% than increment to as per patient tolerance) Total Duration:6 weeks. Duration of each session:15-30 mins. Cool-down: 5 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Home Plan
Description: * Positions to ease breathlessness~* Controlled breathing/Deep breathing\*10 Reps\* TD,s~* Progressive Muscle Relaxation Exercises.~* ROM \& Flexibility Exercises. 3 days a week for 6 weeks.
Study: NCT04863079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: Pembrolizumab 200 mg IV, Q3W, up to one year or disease progression or intolerance.
Study: NCT05926154

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical tourniquet pressure selection
Description: Limb occlusion pressure is calculated using the formulation by Graham: LOP = \[(Systolic Pressure - Diastolic Pressure)× (Limb Diameter) / 3 Cuff Width)\] + Diastolic Pressure. One group is LOP + 50 mm Hg and other one is LOP + 100 mmHg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical tourniquet pressure selection
Description: Limb occlusion pressure is calculated using the formulation by Graham: LOP = \[(Systolic Pressure - Diastolic Pressure)× (Limb Diameter) / 3 Cuff Width)\] + Diastolic Pressure. One group is LOP + 50 mm Hg and other one is LOP + 100 mmHg
Study: NCT05831748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic Exercise
Description: Classic exercise group consists of straight leg raising, back extensor strengthening, and abdominal strengthening exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Pilates
Description: In the Clinical pilates group, pilates exercises will be given. Clinical pilates exercises improve back extensors, trunk flexors, and pelvis stabilization. These exercises will be applied along with breathing exercises.
Study: NCT06304077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forest
Description: Participants in the intervention groups will receive 5 VR training sessions over 10 days in addition to their usual care. Each participant will wear the HMD for 25 minutes in each of this training sessions, whereby he or she will first sit for 5 minutes looking at a forest-landscape. This is followed by 20 minutes of independent exploration of the virtual environment by walking. Depending on the user's gait stability, walking aids (such as walking sticks or rollators) may be used. This phase aims at keeping the participant walking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urban
Description: Participants in the intervention groups will receive 5 VR training sessions over 10 days in addition to their usual care. Each participant will wear the HMD for 25 minutes in each of this training sessions, whereby he or she will first sit for 5 minutes looking at an urban-landscape. This is followed by 20 minutes of independent exploration of the virtual environment by walking. Depending on the user's gait stability, walking aids (such as walking sticks or rollators) may be used. This phase aims at keeping the participant walking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rural
Description: Participants in the intervention groups will receive 5 VR training sessions over 10 days in addition to their usual care. Each participant will wear the HMD for 25 minutes in each of this training sessions, whereby he or she will first sit for 5 minutes looking at a rural-landscape. This is followed by 20 minutes of independent exploration of the virtual environment by walking. Depending on the user's gait stability, walking aids (such as walking sticks or rollators) may be used. This phase aims at keeping the participant walking.
Study: NCT04618133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early time-restricted eating
Description: Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from 6am to 2pm, with a 1-hour allowance according to their daily routine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late time-restricted eating
Description: Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from noon to 8pm, with a 1-hour allowance according to their daily routine

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Participants will be advised to eat a minimum of 3 meals over the 24-hour cycle, i.e. breakfast from 6am to 9am, lunch from 11am to 2pm, dinner from 6pm to 10pm. Snacks will be allowed between meals
Study: NCT05715723

Intervention type: DRUG
Intervention: Reamberin
Description: Reamberin® in the average daily dose of 10 ml/kg daily
Study: NCT05232851

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT, FDG-PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT, FDG-PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study: NCT05778188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071
Description: RLS-0071 (unit strength 10 mg/mL) will be administered by infusion for a dose level of 3, 10, or 20 mg/kg. Planned infusion duration is 10 minutes for all dose levels.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control (commercial sterile saline) will be administered by infusion at a volume matched to RLS-0071 (3, 10, or 20 mg/kg). Planned infusion duration is 10 minutes for all matched dose levels.
Study: NCT05091749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: troponin measurement
Study: NCT05740085

Intervention type: OTHER
Intervention: Patient information form
Description: Patients will be asked to fill out a patient information form and an osteoporosis awareness form
Study: NCT05648058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam ampule
Description: nefopam ampule 50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diphenhydramine ampule
Description: diphenhydramine ampule 10 mg
Study: NCT05606250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Percutaneous Neuromodulation
Description: Ultrasound guided percutaneous neuromodulation in femoral nerve. Patients were placed in supine lying with the anterior aspect of the hip uncovered. The intervention consisted of the application of a biphasic square wave electric current, with a frequency of 2 Hz, a phase duration of 250μs, and a maximum tolerable intensity to cause an exacerbated muscle contraction for 15minutes in total
Study: NCT04922463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PLASOMA
Description: Treatment with cold plasma device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PLASOMA
Description: Treatment with cold plasma device
Study: NCT06372938

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound measurement
Description: The diagnosis of FGR was made according to the following Delphi criteria . EFW \<3rd percentile or EFW \<10th percentile with Doppler evidence of placental dysfunction (Umbilical artery Doppler (UA) pulsatility index (PI) \>95th percentile, absence of umbilical artery end-diastolic flow (UAEDF), or reverse-UAEDF and/or cerebroplacental ratio (CPR) \<5th percentile).

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound measurement
Description: The diagnosis of FGR was made according to the following Delphi criteria . EFW \<3rd percentile or EFW \<10th percentile with Doppler evidence of placental dysfunction (Umbilical artery Doppler (UA) pulsatility index (PI) \>95th percentile, absence of umbilical artery end-diastolic flow (UAEDF), or reverse-UAEDF and/or cerebroplacental ratio (CPR) \<5th percentile).

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Tests and Inflammatory Markers
Description: The laboratory values were measured at the time of FGR diagnosis (between 32 and 37 weeks of pregnancy). After evaluation of hemoglobin (g/dl), leukocytes (103/μL), monocytes (103/μL), lymphocytes (103/μL), neutrophils (103/μL), platelets (103/μL) and albumin (g/dl), the inflammation values were calculated as follows: ;~* SII = Absolute platelet count (APC)\* Absolute neutrophil count (ANC) / Absolute lymphocyte count (ALC);~* SIRI = Absolute monocyte count (AMC) \* ANC/ ALC;~* NPAR = Proportion of neutrophils (in total leukocytes) (%) × 100/albumin (g/dL).

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Tests and Inflammatory Markers
Description: The laboratory values were measured at the time of FGR diagnosis (between 32 and 37 weeks of pregnancy). After evaluation of hemoglobin (g/dl), leukocytes (103/μL), monocytes (103/μL), lymphocytes (103/μL), neutrophils (103/μL), platelets (103/μL) and albumin (g/dl), the inflammation values were calculated as follows: ;~* SII = Absolute platelet count (APC)\* Absolute neutrophil count (ANC) / Absolute lymphocyte count (ALC);~* SIRI = Absolute monocyte count (AMC) \* ANC/ ALC;~* NPAR = Proportion of neutrophils (in total leukocytes) (%) × 100/albumin (g/dL).
Study: NCT05165355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib (80 mg orally, once daily) for 3 years.
Study: NCT05778578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Universal Basic Income
Description: Universal basic income (UBI) is a system that gives everyone a minimum amount of money regularly, regardless of their income or work status.
Study: NCT05754073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1. Intranasal oxytocin spray
Description: 30 IU, twice daily for 12 months in the experimental arm in double-blinded phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2. Intranasal placebo spray
Description: 30 IU, twice daily for 12 months in the placebo comparator arm in double-blinded phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3. Intranasal Oxytocin spray
Description: 30 IU, twice daily for 6 months in both experimental and placebo comparator arm in open-label phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 3. Intranasal Oxytocin spray
Description: 30 IU, twice daily for 6 months in both experimental and placebo comparator arm in open-label phase
Study: NCT06155747

Intervention type: OTHER
Intervention: Epidemiologic investigation
Description: Identification of:~1. overlaps in source(s) of care between participants with NTM isolates in a healthcare center.~2. environmental NTM isolates that are highly related to respiratory isolates.~3. common water source exposure among subjects with clustered NTM infections via shared home of residence watershed.
Study: NCT05486026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine 30 MG
Description: patient in first group (case) will receive duloxetine tablet 30mg for two weeks then titrated up to duloxetine 30mg BID. Patients will be instructed to take the medication with meals. The for 13 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine 30 MG
Description: patient in first group (case) will receive duloxetine tablet 30mg for two weeks then titrated up to duloxetine 30mg BID. Patients will be instructed to take the medication with meals. The for 13 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nonsteroidal Antiinflammatory Drug
Description: patient in this second group will receive NSAID for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nonsteroidal Antiinflammatory Drug
Description: patient in this second group will receive NSAID for 3 weeks
Study: NCT04809311

Intervention type: DRUG
Intervention: Oral antidiabetetic drugs
Description: During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration

Intervention type: DRUG
Intervention: Basal insulin
Description: During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration

Intervention type: DRUG
Intervention: Basal insulin
Description: During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration

Intervention type: DRUG
Intervention: Glucagon-like peptide-1 (GLP-1)
Description: During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration
Study: NCT05986513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold Pressor Gel Test
Description: This test will allow the research team to induce a painful sensation in participants in a safe, non-invasive, standardized, and short-lasting manner. The protocol for the cold pressor gel test is simple: participants will place their non-dominant hand in the container of cold water for as long as they can up to a maximum of two minutes. If it becomes too painful or uncomfortable during those two minutes, participants can remove their hand from the container. It should be noted again that this is not a treatment for knee OA or chronic pain and will be used to investigate the effects of acute pain in the brain of individuals with a chronic pain condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold Pressor Gel Test
Description: This test will allow the research team to induce a painful sensation in participants in a safe, non-invasive, standardized, and short-lasting manner. The protocol for the cold pressor gel test is simple: participants will place their non-dominant hand in the container of cold water for as long as they can up to a maximum of two minutes. If it becomes too painful or uncomfortable during those two minutes, participants can remove their hand from the container. It should be noted again that this is not a treatment for knee OA or chronic pain and will be used to investigate the effects of acute pain in the brain of individuals with a chronic pain condition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cold Pressor Gel Test
Description: This test will allow the research team to induce a painful sensation in participants in a safe, non-invasive, standardized, and short-lasting manner. The protocol for the cold pressor gel test is simple: participants will place their non-dominant hand in the container of cold water for as long as they can up to a maximum of two minutes. If it becomes too painful or uncomfortable during those two minutes, participants can remove their hand from the container. It should be noted again that this is not a treatment for knee OA or chronic pain and will be used to investigate the effects of acute pain in the brain of individuals with a chronic pain condition.
Study: NCT05146804

Intervention type: OTHER
Group type: OTHER
Intervention: BroccoCress
Description: BroccoCress® is a brand name for an edible plant, broccoli sprouts. BroccoCress® is a product within the group of vegetable sprouts.

Intervention type: OTHER
Group type: OTHER
Intervention: BroccoCress
Description: BroccoCress® is a brand name for an edible plant, broccoli sprouts. BroccoCress® is a product within the group of vegetable sprouts.

Intervention type: OTHER
Group type: OTHER
Intervention: Affilla Cress
Description: Pea sprouts commercially available as Affilla Cress® will be used as placebo in this study since these sprouts do not contain Glucoraphanin/Sulforaphane.

Intervention type: OTHER
Group type: OTHER
Intervention: Affilla Cress
Description: Pea sprouts commercially available as Affilla Cress® will be used as placebo in this study since these sprouts do not contain Glucoraphanin/Sulforaphane.